Provided by Tiger Trade Technology Pte. Ltd.

Bioxcel Therapeutics Inc.

0.7746
-0.0292-3.63%
Volume:655.41K
Turnover:523.31K
Market Cap:24.25M
PE:-0.25
High:0.8330
Open:0.8000
Low:0.7705
Close:0.8038
52wk High:5.25
52wk Low:0.7365
Shares:31.31M
Float Shares:26.89M
Volume Ratio:0.91
T/O Rate:2.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1505
EPS(LYR):-5.7255
ROE:-1766.94%
ROA:-102.43%
PB:-0.21
PE(LYR):-0.14

Loading ...

BioXcel Therapeutics Inc expected to post a loss of 75 cents a share - Earnings Preview

Reuters
·
Mar 23

BioXcel Therapeutics Initiated at Buy by Rodman & Renshaw

Dow Jones
·
Mar 17

BioXcel Therapeutics Closes $8.0 Million Direct Offering

MT Newswires Live
·
Mar 12

Press Release: BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering

Dow Jones
·
Mar 12

BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering

THOMSON REUTERS
·
Mar 11

Why Are BioXcel Therapeutics Shares Down Friday?

Benzinga_recent_news
·
Mar 06

BUZZ-U.S. STOCKS ON THE MOVE -Burlington Stores, Berkshire Hathaway, Bioventus

Reuters
·
Mar 05

BioXcel price target lowered to $6 from $10 at H.C. Wainwright

TIPRANKS
·
Mar 05

BUZZ-BioXcel jumps after mid-stage trial shows drug eases opioid withdrawal symptoms

Reuters
·
Mar 05

BioXcel Therapeutics Shares Rise 21.1% Premarket as Experimental Opioid‑Withdrawal Drug Shows Benefit in Mid-Stage Trial

THOMSON REUTERS
·
Mar 05

BRIEF-Bioxcel Therapeutics Announces Positive Phase 2 Topline Results From Columbia University-Led Study Of BXCL501 For Treatment Of Opioid Withdrawal

Reuters
·
Mar 05

BioXcel Therapeutics Inc: Bxcl501 Demonstrated Clinical Benefits and Favorable Tolerability Profile for Treatment of Opioid Withdrawal Symptoms

THOMSON REUTERS
·
Mar 05

BioXcel Therapeutics Announces Positive Phase 2 Topline Results From Columbia University-Led Study of Bxcl501 for Treatment of Opioid Withdrawal

THOMSON REUTERS
·
Mar 05

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 05